

In Which the Gain is more from Pulmonary Rehabilitation? Asthma or COPD?

Sami Deniz , Hülya Şahin , Gülrü Polat , Ahmet Emin Erbaycu 

Clinic of Chest Diseases, Health Sciences University, İzmir University of Health Sciences Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, İzmir, Turkey

Cite this article as: Deniz S, Şahin H, Polat G, et al. In Which the Gain is more from PR? Asthma or COPD? Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2018.18031

Abstract

OBJECTIVES: Pulmonary rehabilitation (PR) is useful for patients with chronic obstructive pulmonary disease (COPD) but not clear for patients with asthma. The aim of the present study was to evaluate the effectiveness of PR in patients with asthma by comparing patients with COPD. The study was designed as a retrospective case series. We recruited patients with COPD and asthma.

MATERIALS AND METHODS: Demographics, respiratory symptoms, medications, smoking history, comorbidities, exercise capacity, respiratory function tests, and quality of life (QOL) were recorded. Exercise capacity was evaluated by the 6-minute walk test (6MWT), QOL with St. George's Respiratory Questionnaire (SGRQ), 36-item Short Form Health Survey (SF-36) Quality of Life Questionnaire, and Hospital Anxiety and Depression (HAD) Scale.

RESULTS: Forty-two patients with asthma and 25 COPD who completed PR were included in the study. There was no difference in terms of age and sex between the groups ($p=0.100$ and $p=0.365$, respectively); however, body mass index was higher in the asthmatic group ($p=0.007$). Partial oxygen pressure (pO_2) difference and arterial oxygen saturation (SpO_2) difference were significantly higher in the COPD group than in the asthma group after PR ($p<0.05$). When the patients were compared before and after PR in both groups, a significant increase was detected in exercise capacity and QOL (6MWT, HADa, SGRQ, and SF-36 in all domains) ($p<0.05$). When two groups are contrasted according to the difference between pre- and post-PR of variables, there was no significant difference except pO_2 , SpO_2 , and Medical Research Council ($p>0.05$).

CONCLUSION: Physicians refer patients with COPD to PR; however, patients with asthma are not generally referred to the same frequency. We would like to emphasize that PR may be as effective as COPD in asthma.

KEYWORDS: Asthma, COPD, pulmonary rehabilitation

Received: 17.03.2018

Accepted: 01.10.2018

Available Online Date: 01.04.2019

INTRODUCTION

According to the American Thoracic Society (ATS) and the European Respiratory Society, pulmonary rehabilitation (PR) is a "comprehensive intervention based on a thorough patient assessment followed by patient-tailored therapies, which include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of individuals with chronic respiratory disease (COPD) and to promote the long-term adherence of health-enhancing behaviors" [1].

There is evidence that physical activity is decreased in COPD [2]. This results to reduced quality of life (QOL), increased rates of hospitalization, and mortality [3,4]. PR enhances exercise capacity, perception of dyspnea, QOL, and anxiety and depression; reduces hospitalization and duration of hospital stay; and accelerates recovery after hospitalization due to exacerbation (evidence A) [5,6].

Asthma leads to intermittent episodes of wheezing, dyspnea, chest tightness, and coughing [7]. Some patients with asthma may avoid physical activity due to dyspnea or for fear of triggering symptoms. Adults with asthma have been reported to have lower levels of physical activity than their peers, in addition to their reduced capacity to overcome daily activities, increased levels of psychological distress, and reduced health-related QOL [8,9]. Regular physical activity reduces the risk of asthma exacerbations in asthma [10].

Although it has long been known that exercise training increases physical fitness in asthma, new data reported that exercise training also has important effects on psychosocial outcomes and symptoms. Two trials showed that exercise training

Address for Correspondence: Sami Deniz, Clinic of Chest Diseases, Health Sciences University, İzmir University of Health Sciences Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, İzmir, Turkey

E-mail: sami_deniz@yahoo.com

©Copyright 2019 by Turkish Thoracic Society - Available online at www.turkthoracj.org

improves asthma symptoms, anxiety, depression, and QOL in individuals with moderate to severe, persistent asthma [11,12].

We aimed to evaluate the efficiency of PR in patients with asthma by comparing patients with COPD.

MATERIAL AND METHODS

This was a retrospective study. Patients referred to the PR unit were included in the study. İzmir University of Health Sciences Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital approved the study (date: 19/07/2017; no: 49109414-806.02.02).

Subject Selection

We recruited patients with COPD and asthma. All patients with asthma were enrolled in the study. There were 8 female and 17 male patients with COPD. Only patients with COPD and no other diseases were included. Patients with dyspnea, decreased exercise capacity, and limitation of daily living activities were accepted to the PR program. Patients with both COPD and asthma who were having difficulty in performing daily activities were also included in the study. Patients who were suffering from acute infection and some impairment, such as orthopedic, neurologic, and/or cardiovascular status, that may render the patient incapable of completing the exercise training after all patients were examined by a cardiologist and a physical therapist were excluded from the study. Subjects who were having compliance or transportation problems, left the program voluntarily, hospitalized due to infections or other reasons, had to leave due to a newly developed disease, or had financial difficulties were also excluded. All evaluations of patients referred to PR were conducted in our hospital routinely.

Measurements

Demographic data, respiratory complaints, treatments, smoking history, and comorbidities were recorded based on self reports at the beginning of the program. Before inclusion to the PR program, patient data were recorded.

Respiratory Functions

Body plethysmography (Zan 500, Germany) and carbon monoxide diffusion capacity (DLCO) (Zan 300) were recorded. The %predicted values of forced expiratory volume (FEV₁), forced vital capacity (FVC), inspiratory capacity, vital capacity, residual volume, total lung capacity, DLCO, and FEV₁/FVC ratio were recorded before and after PR.

Assessment of Dyspnea

The Medical Research Council (MRC) dyspnea scale, which consists of five items ranging between 1 and 5, was used to determine the severity of patients' shortness of breath. A score of "1" represents the best level and "5" the poorest [13]. After the 6-minute walk test (6MWT), dyspnea scores were evaluated by the Borg Scale [14].

Exercise Capacity

The 6MWT was performed according to the ATS guidelines, and the distance walked for 6 minutes was recorded before and after PR [15].

Quality of Life

The St. George's Respiratory Questionnaire (SGRQ) was used to detect disease-specific QOL [16]. High scores show wors-

ened disease and increased symptoms. The overall QOL was evaluated by the 36-item Short Form Health Survey (SF-36) Quality of Life Questionnaire [17]. Increased scores represent improved QOL.

Psychological Symptoms

The Hospital Anxiety and Depression (HAD) Scale, which consists of 14 questions, was used to determine the psychological status of the patients. Anxiety and depression score is ranked as 0-7: normal, 8-11: borderline, and >11 anxiety or depression [18,19].

Interventions

Pulmonary physiotherapy and rehabilitation sessions, lasting for 2 h, were performed twice a week for 2 weeks to all patients who participated in the program. The exercise program included breathing exercises consisting of pursed-lip, diaphragmatic ventilation and thoracic expansion, relaxation and stretching, peripheral muscle strength, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing posture were taught. Bronchial hygiene techniques were applied to all patients with COPD and only required patients with asthma. After respiratory physiotherapy education, upper and lower extremity stretching and strengthening exercises were performed. All strengthening exercises were started without any weight. According to the Borg Scale, a half kilogram weight was added every four periods of exercises. The treadmill and bicycle/arm ergometers were used for aerobic exercises [1,6]. Patients were trained at 60%-90% of the maximum heart rate. In addition, we used the Borg dyspnea scores to regulate exercise. Exercise intensity increased according to patient progress. During exercise, we used pulse oximetry to supervise patients (both COPD and asthma), and if arterial oxygen saturation (SpO₂) decreased <90%, oxygen supplementation was provided. Aerobic exercises were performed for 30 min, which consisted of 15-minute treadmill and 15-minute static bicycle exercises [1,6,20]. An arm ergometer was used for patients with joint disorder or lower extremity disability. We aimed to compare gains from PR between asthma and COPD in the present study.

Statistical Analysis

Data were imported to the Statistical Package for the Social Sciences program version 22 (SPSS Statistics IBM Corp.; Armonk, NY, USA), and statistical analysis was also made using the same program. Data were presented as mean, standard deviation, median, minimum, and maximum values for continuous variables, and the normal distribution of these variables was examined. Nominal variables were expressed by their frequencies and percentages and compared by cross tables. Independent groups were compared using the chi-square test. A normal distribution for all the variables was not present as explored by a normality test, graphical analysis, and by considering the sample size. Comparison of these variables was performed via nonparametric tests. The Mann-Whitney U test was used in independent groups, and the Wilcoxon signed-rank test was used in repeated measurements. For all the statistical comparison tests, the probability of a type 1 error was =0.05 and two-sided. A p value <0.05 was considered statistically significant.

RESULTS

Forty-two patients with asthma and 25 COPD who completed PR were included in the study (8 male patients in each group). While 27 patients with asthma had comorbidities (hypertension

(HT), diabetes mellitus, and coronary artery disease), 9 patients with COPD had the same comorbidities, and there was no significant difference between the groups. The most frequent comorbidity was HT. Oxygen use, hospital admission, and smoking pack-years were higher in patients with COPD ($p < 0.05$).

Table 1. Comparison of variables between pre- and post-PR in asthma

Variables	Asthma (n=42)		Post-PR		p
	Pre-PR Mean±SD	Median (min-max)	Mean±SD	Median (min-max)	
Age (years)	55.3±10.4	56 (33-75)			
BMI (kg/m ²)	30.8±4.9	32 (20-40)			
Smoking (pack-years)	28.3±22	23 (3-80)			
FEV ₁ (%predicted)	78.9±14.1	80 (41-102)	78±14.1	79 (41-100)	0.093
FEV ₁ /FVC	78.9±7.2	77.5 (67-100)	80.3±9.2	77.5 (66-104)	0.400
IC (%predicted)	92.5±20.5	91 (65-142)	89.1±23.7	86 (51-135)	0.297
VC (%predicted)	90.4±14.4	89 (70-129)	86.9±12.8	84 (65-108)	0.162
PEF (%predicted)	60.6±21.6	64.5 (29-99)	61±20.1	60 (31-96)	0.850
RV (%predicted)	129.7±46.3	124 (68-228)	131.6±40.4	124 (49-209)	0.545
DLCO	55.6±9.9	55 (40-74)	56.3±10.1	60 (34-73)	0.583
pO ₂ (mmHg)	83.3±8.2	84.5 (67-100)	83.7±10.6	84.5 (60-109)	0.769
pCO ₂ (mmHg)	38±4.4	38.4 (27-46)	38.5±4.2	39 (30-49)	0.605
SpO ₂ (%)	96.4±1.5	96.7 (93-100)	96.1±1.8	96 (91-99)	0.519
pH	7.40±0.04	7.42 (7.35-56)	7.41±0.04	7.41 (7.32-51)	0.711
6MWT (m)	374±93	375 (120-550)	415±96	415 (88-570)	<0.001
Borg difference	1.7±1.5	1 (0-4.5)	1.2±1.1	1 (0-4)	0.003
Pulse difference	18.5±10.4	16 (3-40)	23.2±10.9	21.5 (4-51)	0.075
SpO ₂ difference	0.6±1.5	1 (-3-4)	0.7±1.7	0.5 (-3-7)	0.765
SGRQ					
Symptom	58.6±21.5	61.2 (13-93)	48.9±17.7	51.4 (9-86)	<0.001
Activity	66.9±23.4	66.9 (7-100)	52.4±26.9	53.5 (0-100)	<0.001
Impact	50.3±23	50 (13-93)	37.6±24.2	35.6 (4-91)	<0.001
Total	56.7±20.8	58.1 (13-94)	44±22.4	48 (7-90)	<0.001
SF-36					
Physical functioning	48.6±29.8	55 (0-95)	63.4±29.8	70 (0-100)	<0.001
Social functioning	56.5±27.5	62.5 (0-100)	65.4±25.4	62.5 (13-100)	0.050
Role physical	23.8±37	0 (0-100)	55.3±44.3	75 (0-100)	<0.001
Role emotional	29.6±39.6	0 (0-100)	57.1±41.1	66.6 (0-100)	<0.001
General health	38.5±25.9	35.5 (-25-92)	43.6±27	47.5 (-25-97)	0.063
Mental health	53±23.8	52 (16-100)	61.7±24.8	66 (12-100)	0.015
Bodily pain	51.1±29.9	41 (0-100)	66.6±25.7	67 (22-100)	<0.001
Vitality	43.2±28.4	37.5 (0-100)	58.6±22	57.5 (15-100)	<0.001
HADa	9.5±5.5	8.5 (1-21)	7.3±4.6	6.5 (0-19)	<0.001
HADd	7.7±4	8 (0-20)	5.9±4.1	5.5 (0-16)	<0.001
MRC	2.9±1.1	3 (1-5)	2.2±1	2 (1-5)	<0.001
ACT	14.1±5.5	13.5 (5-23)	20.2±4.2	21.5 (9-25)	<0.001

BMI: body mass index; FEV₁: forced expiratory volume; FVC: forced vital capacity; IC: inspiratory capacity; VC: vital capacity; PEF: peak expiratory flow; RV: residual volume; DLCO: carbon monoxide diffusion capacity; % pred: percent predicted; pO₂: partial oxygen pressure; pCO₂: partial arterial carbon dioxide pressure; SpO₂: arterial oxygen saturation; 6MWT: 6-minute walk test; SGRQ: St. George's Respiratory Questionnaire; SF-36: 36-item Short Form Health Survey; HAD: Hospital Anxiety and Depression Scale; MRC: Medical Research Council; ACT: asthma control test

Table 2. Comparison of variables between pre- and post-PR in COPD

Variables	COPD (n=25)		Post-PR		p
	Pre-PR Mean±SD	Median (min-max)	Mean±SD	Median (min-max)	
Age (years)	59.5±6.8	60 (47-72)			
BMI (kg/m ²)	27.2±5.1	26 (18-39)			
Smoking (pack-years)	43.3±27.6	38 (10-100)			
FEV ₁ (%predicted)	45.7±16.2	47 (20-68)	46.7±15.7	48.5 (21-73)	0.074
FEV ₁ /FVC	57.4±9.2	61.5 (40-67)	59±9.8	62 (33-71)	0.246
IC (%predicted)	65.5±22.8	61 (39-107)	67.5±22.6	65 (40-114)	0.492
VC (%predicted)	70±20.4	71 (41-119)	71.7±19.9	69 (39-118)	0.381
PEF (%predicted)	38.8±12.1	40 (14-58)	43.8±11.8	44 (24-65)	0.013
RV (%predicted)	158.8±53.2	146 (85-273)	151.8±53.8	147 (49-260)	0.122
DLCO	40.8±13.8	44 (17-66)	38.8±14	41 (17-64)	0.069
pO ₂ (mmHg)	73.6±12	74 (51-96)	78.7±11.7	78 (54-102)	0.004
pCO ₂ (mmHg)	42.2±7.2	39 (31-56)	40.4±5	40 (32-50)	0.179
SpO ₂ (%)	94.6±2	94.9 (91-98)	95.8±2	96.2 (91-99)	0.006
pH	7.41±0.02	7.41 (7.38-46)	7.40±0.03	7.41 (7.34-45)	0.326
6MWT (m)	325±93	320 (120-470)	382±96	400 (100-520)	<0.001
Borg difference	2.1±1.1	2 (0-4)	1.3±1.1	1.5 (0-3)	0.018
Pulse difference	16.3±7.2	17.5 (3-31)	18.9±12.2	16 (2-52)	0.397
SpO ₂ difference	2.3±2.4	2 (-2-7)	2.7±2.4	2 (-1-9)	0.453
SGRQ					
Symptom	55.2±16.8	56.7 (21-81)	45.9±17.5	43.3 (5-94)	0.010
Activity	71.3±21.9	72.8 (13-100)	52.7±26.4	48.4 (0-100)	<0.001
Impact	48.2±18.7	45.9 (16-82)	32.9±20.9	28.5 (4-77)	<0.001
Total	56.3±17.1	56.6 (20-87)	41.1±20.4	41.5 (6-87)	<0.001
SF-36					
Physical functioning	41.5±26.8	35 (0-95)	63.2±28.1	65 (0-100)	<0.001
Social functioning	53.8±30.7	50 (0-100)	76±21.9	75 (25-100)	0.003
Role physical	22.8±36.8	0 (0-100)	69.5±38.4	75 (0-100)	0.001
Role emotional	24.6±35.1	0 (0-100)	65.2±34	66.6 (0-100)	0.002
General health	42.1±24.6	40 (0-85)	56.4±23.5	56 (5-95)	0.002
Mental health	54.9±23.6	52 (8-96)	70.2±23.7	76 (24-100)	0.001
Bodily pain	43.3±21.9	42 (0-100)	66.6±24.3	62 (22-100)	0.001
Vitality	40±25	50 (0-80)	61.7±22.9	65 (15-100)	<0.001
HADa	8±4.5	8 (0-20)	6.2±4.5	5 (1-18)	0.011
HADd	7±4.7	8 (1-15)	5.7±4.6	6 (0-19)	0.143
MRC	3.2±0.9	3 (1-5)	2.1±1	2 (1-4)	<0.001

BMI: body mass index; FEV₁: forced expiratory volume; FVC: forced vital capacity; IC: inspiratory capacity; VC: vital capacity; PEF: peak expiratory flow; RV: residual volume; DLCO: carbon monoxide diffusion capacity; % pred: percent predicted; pO₂: partial oxygen pressure; pCO₂: partial arterial carbon dioxide pressure; SpO₂: arterial oxygen saturation; 6MWT: 6-minute walk test; SGRQ: St. George's Respiratory Questionnaire; SF-36: 36-item Short Form Health Survey; HAD: Hospital Anxiety and Depression Scale; MRC: Medical Research Council

There were significant differences in 6MWT, Borg difference, SGRQ in all domains, SF-36 (except general health), HAD, MRC, and asthma control test after PR in asthma (Table 1). Significant differences were also found in partial oxygen pressure (pO₂), SpO₂, Borg difference, SGRQ, SF-36, HAD, and MRC in patients with COPD (Table 2).

When comparing two groups in terms of basal variables, there was no significant difference in terms of age and gender between the two groups (p=0.100 and p=0.365, respectively); however, there were differences with body mass index (BMI) (higher in asthma), PFT, 6MWT (lower in COPD), SpO₂ difference (higher difference in COPD), and smoking (higher in COPD) (Table 3).

Table 3. Comparison of basal values between patients with COPD and asthma

Variables	Asthma (42)		COPD (25)		p
	Mean±SD	Median (min-max)	Mean±SD	Median (min-max)	
Age (years)	55.3±10.4	56 (33-75)	59.5±6.8	60 (47-72)	0.100
BMI (kg/m ²)	30.8±4.9	32 (20-40)	27.2±5.1	26 (18-39)	0.007
Smoking (pack-years)	28.3±22	23 (3-80)	43.3±27.6	38 (10-100)	0.079
FEV ₁ (%predicted)	78.9±14.1	80 (41-102)	45.7±16.2	47 (20-68)	0.000
FEV ₁ /FVC	78.9±7.2	77.5 (67-100)	57.4±9.2	61.5 (40-67)	0.000
IC (%predicted)	92.5±20.5	91 (65-142)	65.5±22.8	61 (39-107)	0.001
VC (%predicted)	90.4±14.4	89 (70-129)	70±20.4	71 (41-119)	0.001
PEF (%predicted)	60.6±21.6	64.5 (29-99)	38.8±12.1	40 (14-58)	0.003
RV (%predicted)	129.7±46.3	124 (68-228)	158.8±53.2	146 (85-273)	0.075
DLCO	55.6±9.9	55 (40-74)	40.8±13.8	44 (17-66)	0.001
pO ₂ (mmHg)	83.3±8.2	84.5 (67-100)	73.6±12	74 (51-96)	0.001
pCO ₂ (mmHg)	38±4.4	38.4 (27-46)	42.2±7.2	39 (31-56)	0.041
SpO ₂ (%)	96.4±1.5	96.7 (93-100)	94.6±2	94.9 (91-98)	0.001
pH	7.40±0.04	7.42 (7.35-56)	7.41±0.02	7.41 (7.38-46)	0.498
6MWT (m)	374±93	375 (120-550)	325±93	320 (120-470)	0.049
Borg difference	1.7±1.5	1 (0-4.5)	2.1±1.1	2 (0-4)	0.244
Pulse difference	18.5±10.4	16 (3-40)	16.3±7.2	17.5 (3-31)	0.670
SatO ₂ difference	0.6±1.5	1 (-3-4)	2.3±2.4	2 (-2-7)	0.005
SGRQ					
Symptom	58.6±21.5	61.2 (13-93)	55.2±16.8	56.7 (21-81)	0.391
Activity	66.9±23.4	66.9 (7-100)	71.3±21.9	72.8 (13-100)	0.484
Impact	50.3±23	50 (13-93)	48.2±18.7	45.9 (16-82)	0.742
Total	56.7±20.8	58.1 (13-94)	56.3±17.1	56.6 (20-87)	0.896
SF-36					
Physical functioning	48.6±29.8	55 (0-95)	41.5±26.8	35 (0-95)	0.253
Social functioning	56.5±27.5	62.5 (0-100)	53.8±30.7	50 (0-100)	0.724
Role physical	23.8±37	0 (0-100)	22.8±36.8	0 (0-100)	0.849
Role emotional	29.6±39.6	0 (0-100)	24.6±35.1	0 (0-100)	0.744
General health	38.5±25.9	35.5 (-25-92)	42.1±24.6	40 (0-85)	0.656
Mental health	53±23.8	52 (16-100)	54.9±23.6	52 (8-96)	0.726
Bodily pain	51.1±29.9	41 (0-100)	43.3±21.9	42 (0-100)	0.508
Vitality	43.2±28.4	37.5 (0-100)	40±25	50 (0-80)	0.645
HADa	9.5±5.5	8.5 (1-21)	8±4.5	8 (0-20)	0.382
HADd	7.7±4	8 (0-20)	7±4.7	8 (1-15)	0.483
MRC	2.9±1.1	3 (1-5)	3.2±0.9	3 (1-5)	0.309

BMI: body mass index; FEV₁: forced expiratory volume; FVC: forced vital capacity; IC: inspiratory capacity; VC: vital capacity; PEF: peak expiratory flow; RV: residual volume; DLCO: carbon monoxide diffusion capacity; pO₂: partial oxygen pressure; pCO₂: partial arterial carbon dioxide pressure; SpO₂: arterial oxygen saturation; 6MWT: 6-minute walk test; SatO₂: oxygen saturation; SGRQ: St. George's Respiratory Questionnaire; SF-36: 36-item Short Form Health Survey; HAD: Hospital Anxiety and Depression Scale; MRC: Medical Research Council

When the groups were compared according to the differences between pre- and post-PR of variables, there were no significant differences (except pO₂, SpO₂, and MRC) (p>0.05) (Table 4).

DISCUSSION

Pulmonary rehabilitation improves exercise tolerance, reduces symptoms, and improves the QOL for COPD. It is now

recognized increasingly that PR also improves clinical outcomes for individuals with many respiratory disorders other than COPD. Although PR programs have a well established role in COPD treatment, studies about PR effects on patients with asthma are sparse [1].

Asthma is one of the most common chronic diseases worldwide with an estimated 300 million people affected [7]. Even

Table 4. Comparison of differences between pre- and post-PR of variables

Variables	Asthma (42)		COPD (25)		p
	Mean±SD	Median (min-max)	Mean±SD	Median (min-max)	
Δ FEV ₁	-1.9±5.5	-1.5 (-13-8)	1.3±3.2	1.5 (-4-5)	0.09
Δ FEV ₁ /FVC	1.45±6.9	0 (-14-21)	0.9±2.2	1 (-12-16)	0.56
Δ IC	-3.4±0.45	-5 (-28-22)	1.9±11.4	2 (-21-25)	0.16
Δ VC	-3.4±10.2	-3 (-22-19)	1.7±8.3	1 (-17-20)	0.10
Δ PEF	0.3±7.7	-0.5 (-15-14)	5±6.9	6 (-12-16)	0.06
Δ RV	1.9±30.9	4 (-59-60)	-7.2±20.7	-7.5 (-49-39)	0.15
Δ DLCO	0.7±8.1	1 (-18-18)	-2±4.4	-1 (-16-3)	0.14
Δ pO ₂	0.3±8.9	-0.7 (-20-19)	5±9.1	5.3 (-21-25)	0.04
Δ pCO ₂	0.4±4.4	0.2 (-8-97)	-1.8±5.9	-2.6 (-12.5-9)	0.16
Δ SpO ₂	-0.2±1.8	0 (-3.5-3)	1.3±2.2	1 (-4-6.9)	0.02
Δ pH	0±0.04	0 (-0.1-0.09)	-0.01±0.04	0 (-0.09-0.05)	0.74
Δ 6MWT	41.1±28.6	40 (-32-100)	57±39.5	50 (-20-150)	0.09
Δ Borg difference	-0.6±1.2	-0.2 (-3-1)	-0.8±1.4	-1 (-3.5-2)	0.35
Δ Pulse difference	6.1±12.5	2 (-12-35)	2.6±12.9	2 (-19-28)	0.59
Δ SpO ₂ difference	0.1±1.8	0 (-5-4)	0.04±2.4	0 (-5-5)	0.82
SGRQ					
Δ Symptom	-9.7±17.2	-8.5 (-47-45.1)	-9.3±16.2	-10 (-55-17.5)	0.90
Δ Activity	-14.4±19.8	-7.2 (-68.4-19)	-18.6±17.4	-14 (-67.5-6)	0.25
Δ Impact	-12.7±19.5	-11 (-75-35.2)	-15.3±15.2	-15 (-42-14.3)	0.41
Δ Total	-12.7±16.4	-9.6 (-66-23.8)	-15.3±12.2	-15 (-39-8.8)	0.34
SF-36					
Δ Physical functioning	14.7±24	12.5 (-35-85)	21.7±19.4	25 (-10-65)	0.18
Δ Social functioning	8.9±25.2	12.5 (-50-50)	22.2±30	12.5 (-25-87)	0.21
Δ Role physical	31.5±43.8	12.5 (-50-100)	46.7±41.5	50 (0-100)	0.17
Δ Role emotional	27.5±39.8	0 (-33.3-100)	40.5±46	33.3 (-33-100)	0.23
Δ General health	5.1±17.2	7.5 (-32-37)	14.3±17.6	11 (-20-52)	0.10
Δ Mental health	8.6±20.5	6 (-36-52)	15.3±19.5	16 (-16-76)	0.22
Δ Bodily pain	15.5±20.9	15.5 (-32-68)	23.2±25.7	22 (-39-68)	0.13
Δ Vitality	15.4±20.4	14.5 (-20-65)	21.7±20.6	15 (0-85)	0.29
Δ HADa	-2.2±3.8	-1.5 (-14-8)	-1.8±2.9	-2 (-7-4)	0.90
Δ HADd	-1.8±2.8	-1.5 (-11-3)	-1.2±3.7	-1 (-9-6)	0.40
Δ MRC	-0.7±0.8	-1 (-3-0)	-1±0.5	-1 (-2-0)	0.02

FEV₁: forced expiratory volume; FVC: forced vital capacity; IC: inspiratory capacity; VC: vital capacity, PEF: peak expiratory flow; RV: residual volume; DLCO: carbon monoxide diffusion capacity; pO₂: partial oxygen pressure; pCO₂: partial arterial carbon dioxide pressure; SpO₂: arterial oxygen saturation; 6MWT: 6-minute walk test; SGRQ: St. George's Respiratory Questionnaire; SF-36: 36-item Short Form Health Survey; HAD: Hospital Anxiety and Depression Scale; MRC: Medical Research Council

though effective medications are available, asthma is still incurable and poorly controlled for many patients [21]. Patients with asthma are commonly enrolled in PR programs in Europe and in North America [22]. Only very few randomized studies regarding the efficiency of multidisciplinary PR program in asthma have been published [23,24].

It is well established that exercise improves physical fitness without any adverse effects on asthma control. Patients with asthma present lower levels of physical fitness and cardiopulmonary conditioning [25]. Low physical activity levels are

associated with more symptoms, higher risk of exacerbations, and lower health-related QOL in patients with asthma [26].

Physical exercise improves cardiopulmonary fitness, resulting in lower respiratory rate during activity. With lower respiratory rate during activity, bronchoconstriction during exercise becomes less likely [25]. Recent studies have also showed that regular exercise results in a reduction of airway inflammation, thus improving bronchioles patency [27].

The present study was conducted to assess the effect of PR on patients with asthma and COPD and to determine which

gains more from PR. There was no any significance in lung function variables before and after PR of both asthma and COPD groups, which is compatible with the findings in the literature. However, improvement in pO_2 and SpO_2 was significantly higher in the COPD group than in the asthma group after PR. This was attributed to low levels of these values at the beginning in the COPD group. BMI was higher in the asthmatic group as expected.

When patients were compared before and after PR, in both groups, there was a significant change in the QOL, exercise capacity, and anxiety and depression scores. A number of studies have reported significant differences between the groups in the QOL in a mixed group of patients and in patients with COPD in favor of the groups receiving the rehabilitation program [24]. Even though other studies have shown that PR may result to an improvement in the QOL of patients with COPD, the present study showed that these results may also be obtained in patients with asthma. Several questionnaires have been used to detect QOL as outcomes of PR. In the present study, QOL was evaluated by the SGRQ and SF-36. Our results presented an increase in SGRQ scores in both groups, but difference between the two disease groups was not statistically significant.

When compared with pre- and post-PR in two groups separately, patients walked 41 m better in the 6MWT in the asthma group, whereas 57 m better in the pre-PR in the COPD group. These findings were similar with two previous studies [23,24]. The distance walked by the COPD group was significantly higher, but gain in exercise capacity was not significantly higher in the COPD group after PR. This may be clarified by the severity of disease between patients in the asthma and COPD groups.

Despite being not statistically significant, anxiety and depression scores improved more in the asthma group. The baseline scores were also higher in the asthma group. It may be said that physical activity improves anxiety and depression scores more in patients with asthma. The symptom evaluated in the present study was dyspnea during activity, since this is the symptom that defines the need for referral to PR according to the British Thoracic Society guidelines [28]. At the end of PR, there was a statistically significant improvement in dyspnea as assessed by the MRC score in two groups. In addition, there was a significant difference in favor of the COPD group, meaning that the COPD group gains more according to improvement in symptoms. Anxiety and depression scores were also significantly improved after PR in both disease groups.

In the present study, we cannot provide any results about the effect of PR on emergency service admission and hospital stay because they were beyond the scope of the study. However, in studies conducted on this subject, PR has reduced both emergency room and hospital admissions in both asthma and COPD patient groups [22]. In addition to the two randomized controlled studies, few observational studies have been published [29-32]. They have reported positive effects pertaining to QOL, symptoms, and exercise capacity similar to the present study. In a study of patients with COPD and asthma, as in the present study, similar gains were deter-

mined in community-based as in outpatient hospital-based programs [24]. The present study confirms the usefulness of an outpatient-based rehabilitation program.

The present study adds to the evidence that supports the beneficial role of PR in both patients with asthma and COPD. The PR program resulted in improvement in perception of dyspnea, exercise capacity, and life quality with statistical significance in the asthma and COPD groups, but there was no difference between the two groups in terms of gain. Physicians refer patients with COPD to the PR unit; however, patients with asthma are not generally referred to PR in the same frequency. We would like to emphasize that PR may be as effective as COPD in asthma.

Ethics Committee Approval: Ethical approval was obtained by Health Sciences University, İzmir University of Health Sciences Dr. Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital (date: 19/07/2017; no: 49109414-806.02.02).

Informed Consent: Due to the retrospective design of the study, informed consent was not taken.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - H.Ş., S.D.; Design - S.D.; Supervision - S.D.; Resources - H.Ş.; Materials - H.Ş.; Data Collection and/or Processing - H.Ş.; Analysis and/or Interpretation - S.D.; Literature Search - S.D.; Writing Manuscript - S.D., G.P.; Critical Review - S.D., G.P., A.E.E.

Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

1. Spruit MA, Singh SJ, Garvey C, et al; on behalf of the ATS/ERS Task Force on Pulmonary Rehabilitation. An Official American Thoracic Society/ European Respiratory Society Statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013;188:13-64. [\[CrossRef\]](#)
2. Jenkins CR, Thompson PJ, Gibson PG, et al. Distinguishing asthma and chronic obstructive pulmonary disease: why, why not and how? *Med J Aust* 2005;183(1 Suppl):S35-7.
3. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. *Eur Respir J* 2014;44:1521-37. [\[CrossRef\]](#)
4. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. *Thorax* 2006;61:772-8. [\[CrossRef\]](#)
5. From the Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease (GOLD) 2015. [Updated 2015 January]. Available from: <http://www.goldcopd.org>
6. Nici L, Donner C, Wouters E, et al. American Thoracic Society/ European Respiratory Society statement on pulmonary rehabilitation. *Am J Respir Crit Care Med* 2006;173:1390- 413. [\[CrossRef\]](#)
7. Global Initiative for Asthma: GINA Report, Global Strategy for Asthma Management and Prevention - updated 2015. Available from: (www.ginasthma.org).

8. Wertz DA, Pollack M, Rodgers K, et al. Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. *Ann Allergy Asthma Immunol* 2010; 105: 118-23. [\[CrossRef\]](#)
9. Adams RJ, Wilson DH, Taylor AW, et al. Psychological factors and asthma quality of life: a population based study. *Thorax* 2004;59:930-5. [\[CrossRef\]](#)
10. Garcia-Aymerich J, Varraso R, Antó JM, et al. Prospective study of physical activity and risk of asthma exacerbations in older women. *Am J Respir Crit Care Med* 2009;179:999-1003. [\[CrossRef\]](#)
11. Mendes FA, Gonçalves RC, Nunes MP, et al. Effects of aerobic training on psychosocial morbidity and symptoms in patients with asthma: a randomized clinical trial. *Chest* 2010;138:331-7. [\[CrossRef\]](#)
12. Turner S, Eastwood P, Cook A, et al. Improvements in symptoms and quality of life following exercise training in older adults with moderate/severe persistent asthma. *Respiration* 2011;81:302-10. [\[CrossRef\]](#)
13. Sweer L, Zwillich CW. Dyspnea in the patient with chronic obstructive pulmonary disease. Etiology and management. *Clin Chest Med* 1990;11:417-45.
14. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;14:377-81. [\[CrossRef\]](#)
15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Care Med* 2002;166:111-7. [\[CrossRef\]](#)
16. Polatlı M, Yorgancıoğlu A, Aydemir Ö, et al. Validity and reliability of Turkish version of St. George's respiratory questionnaire. *Tuberk Toraks* 2013;61:81-7. [\[CrossRef\]](#)
17. Koçyiğit H, Aydemir Ö, Fişek G, et al. Validity and reliability of Turkish version of Short form SF-36. *Turk J Drugs Ther* 1999;12:102-6.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361-70. [\[CrossRef\]](#)
19. Aydemir Ö. Validity and Reliability of Turkish Version of Hospital Anxiety and Depression Scale. *Türk Psikiyatri Derg* 1997;8:280-7.
20. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. *Respirology* 2008;13:394-9. [\[CrossRef\]](#)
21. Price D, Fletcher M, van der Molen T. Asthma control and management in 8000 European patients: the REcognize Asthma and Link to Symptoms and Experience (REALISE) survey. *NPJ Prim Care Respir Med* 2014;24:14009. [\[CrossRef\]](#)
22. Spruit MA, Pitta F, Garvey C, et al. Differences in content and organisational aspects of pulmonary rehabilitation programmes. *Eur Respir J* 2014;43:1326-37. [\[CrossRef\]](#)
23. Nathell I. Effects on sick leave of an inpatient rehabilitation programme for asthmatics in a randomized trial. *Scand J Public Health* 2005;33:57-64. [\[CrossRef\]](#)
24. Cambach W, Chadwick-Straver RV, Wagenaar RC, et al. The effects of a community based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. *Eur Respir J* 1997;10:104-13. [\[CrossRef\]](#)
25. Carson KV, Chandratilleke MG, Picot J, et al. Physical training for asthma. *Cochrane Database Syst Rev* 2013;9:1-64. [\[CrossRef\]](#)
26. Rochester CL, Fairburn C, Crouch RH. Pulmonary rehabilitation for respiratory disorders other than chronic obstructive pulmonary disease. *Clin Chest Med* 2014;35:369-89. [\[CrossRef\]](#)
27. Eichenberger PA, Diener SN, Kofmehl R, et al. Effects of exercise training on airway hyperreactivity in asthma: a systematic review and meta-analysis. *Sports Med* 2013;43:1157-70. [\[CrossRef\]](#)
28. Bolton CE, Bevan-Smith EF, Blakey JD, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults. *Thorax* 2013;68(Suppl 2):ii1-30. [\[CrossRef\]](#)
29. Emtner M, Finne M, Stalenheim G. A 3 year follow-up of asthmatic patients participating in a 10 week rehabilitation program with emphasis on physical training. *Arch Phys Med Rehabil* 1998;79:539-44. [\[CrossRef\]](#)
30. Emtner M, Herala M, Stalenheim G. High intensity physical training in adults with asthma. A 10 week rehabilitation program. *Chest* 1996;109:323-30. [\[CrossRef\]](#)
31. Foglio K, Bianchi L, Bruletti G, et al. Long term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. *Eur Respir J* 1999;13:125-32. [\[CrossRef\]](#)
32. Lingner H, Ernst S, Grobetschenning A, et al. Asthma control and health related quality of life one year after inpatient pulmonary rehabilitation: the ProKAR Study. *J Asthma* 2015;52:614-21. [\[CrossRef\]](#)